Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01604590 · ClinicalTrials.gov registry record
Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme
A clinical trial, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- 13
- Enrollment target
NCT01604590: Completed study, sponsored by Medical University of South Carolina.
NCT01604590 is a clinical trial that has completed, run by Medical University of South Carolina. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01604590 has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
Study Summary
This study is for subjects with a diagnosis of a brain tumor called glioblastoma that is being treated with bevacizumab. This study will use a new MRI technique to compare the images of blood vessels and tumor structure to the effectiveness of bevacizumab.
Primary Outcome
The MRI parameters will help show the differences between bevacizumab-responsive and bevacizumab non-responsive recurrent glioblastoma
Interventions
- RADIATION Magnetic Resonance Imaging (MRI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-07 |
| Est. Completion | 2014-09 |
What the finished NCT01604590 record still lists
NCT01604590 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Magnetic Resonance Imaging (MRI) is the first listed.
NCT01604590 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01604590 about?
NCT01604590 is a clinical study titled "Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme". This study is for subjects with a diagnosis of a brain tumor called glioblastoma that is being treated with bevacizumab. This study will use a new MRI technique to compare the images of blood vessels and tumor structure to the effectiveness of bevacizumab.
What is the current status of trial NCT01604590?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2012-07. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01604590?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) (RADIATION).
Who is sponsoring clinical trial NCT01604590?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia